Vaccines
Ingenia Therapeutics Debuts on KOSDAQ to Accelerate Next-Gen Vascular Antibody Pipeline
Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that its shares have begun t...
August 21, 2026 | News
ArkBio Advances Ziresovir into US Phase II Trial for Severe RSV in Infants
Shanghai Ark Biopharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II cli...
August 17, 2026 | News
SK bioscience Seeks South Africa Approval to Begin Phase 1b Trial of RSV Preventive Antibody RSM01
Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months Company expands its global portfo...
August 17, 2026 | News
Seegene Advances Comprehensive HPV and STI PCR Testing with Large-Scale Clinical Evidence
STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive case...
July 29, 2026 | News
India Approves First Dengue Vaccine as Cases Surge 11-Fold Over Two Decades
The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades[1] Takeda's de...
July 22, 2026 | News
West Launches Synchrony™ Prefillable Syringe System for Biologics and Vaccines in Southeast Asia
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced the av...
July 10, 2026 | News
After the Rush: APAC's mRNA and Vaccine Capacity Hangover
In June 2022, South Korea had something it had wanted for two years: a COVID-19 vaccine of its own. SKYCovione, developed by SK bioscience with the U...
July 08, 2026 | Analysis
Matica Bio Partners with VaxDome to Advance Novel Intranasal Antiviral Vaccine Platform into Clinical Trials
Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotec...
July 08, 2026 | News
Immunomic Therapeutics Doses First Patient in Phase 1 Trial of saRNA Allergy Vaccine in Japan
First patient dosed less than one month after PMDA clearance, demonstrating rapid clinical execution Next-generation UNITE® saRNA-based immunother...
July 07, 2026 | News
SK Bioscience to Lead Gates Foundation-Backed AI Platform for Vaccine Clinical Development
SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. SK bioscience, PATH, Slalom...
July 06, 2026 | News
Colossal Foundation and University of Tasmania Partner to Fight Deadly Tasmanian Devil Cancer with Gene Editing and Vaccines
The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer...
July 01, 2026 | News
CanSinoBIO Secures Argentina Approval for Menhycia Quadrivalent Meningococcal Conjugate Vaccine
CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the "MCV4",...
July 01, 2026 | News
DoH Abu Dhabi and Sanofi Deepen Partnership to Build Next-Generation Vaccine Innovation Hub
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines...
June 24, 2026 | News
SK Bioscience Licenses CDC Rotavirus Vaccine Technology to Advance Global Immunisation Efforts
SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention SK bioscience is jointly investing with t...
June 11, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
